바이오의약품 부형제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2023-2030년)

Biopharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Polyols, Solubilizes & Surfactants/Emulsifiers, Carbohydrates, Specialty Excipients), By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

바이오의약품 부형제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 바이오의약품 부형제 시장 규모는 2030년까지 37억 6,000만 달러에 달할 것으로 예상됩니다.

이 시장은 2023년부터 2030년까지 연평균 5.50%의 CAGR로 성장할 것으로 예상됩니다. 제네릭 시장에 대한 제약사들의 관심 증가, 다기능 부형제 채택 증가, 생물학적 활성 물질의 특허 만료 등이 시장 성장을 촉진하는 주요 요인으로 꼽힙니다. 또한 제조업체의 비용 효율성과 역량, 바이오의약품의 화학적 및 물리적 불안정성이 부형제 개발을 촉진하고 시장을 촉진하고 있습니다.

최근 몇 년 동안 바이오시밀러에 대한 수요가 증가하면서 바이오의약품 부형제에 대한 수요도 증가하고 있습니다. 특허 만료, 정부 자금의 증가, 환자 인구 통계학적 변화, 가격의 상승과 같은 지원 요인이 전 세계적으로 바이오시밀러의 채택을 촉진하고 있습니다. 또한, 신흥 경제국의 의료 인프라가 빠르게 발전함에 따라 바이오제네릭 의약품 생산에 바이오시밀러의 활용이 증가하고 있습니다. 또한, 전 세계적으로 바이오시밀러에 대한 적절한 규제 및 시험 기준을 확보하기 위한 법규가 정비되면서 제조업체의 시장 진입이 용이해지고 있습니다.

또한, 업계에서 다기능 바이오의약품 부형제의 수용 확대도 시장 성장의 원동력이 되고 있습니다. 다기능 바이오의약품 부형제는 바이오의약품 제조 공정을 효율적이고 효과적으로 강화합니다. 관련 이점으로는 제품 품질 향상, 생산성 향상, 운영 비용 절감 등이 있으며, COVID-19 백신의 성공은 효율적인 약물전달 시스템의 사용으로 강화된 효율성에 크게 의존하고 있습니다.

시장의 주요 업체들은 새로운 바이오의약품 부형제 개발 및 출시에 주력하고 있습니다. 예를 들어, DFE Pharma는 2021년 4월 바이오제약 기업의 세계 공급 문제를 해결하기 위해 새로운 부형제 제품군인 'BioHale'을 발표했습니다. 또한, 바이오의약품 부형제 수요 증가로 인해 제조 시설의 지리적 확장이 증가하고 있습니다. 예를 들어, DFE Pharma는 2022년 5월 인도에 새로운 시설을 개설하여 제약사가 적절한 제형을 구현할 수 있도록 부형제를 포함한 신속한 제형 서비스를 제공하고 있습니다.

그러나 바이오의약품 산업의 공급망 문제와 바이오의약품 부형제 시장 개척에 대한 과제는 예측 기간 동안 시장 성장에 걸림돌이 될 것으로 예상됩니다. 바이오의약품에 적합한 부형제를 선택하는 것은 어렵고 복잡한 문제인데, 한 제제에서는 효과적인 부형제가 다른 제제에서는 단백질의 분해와 응집을 유발할 수 있기 때문입니다. 단백질을 안정화하기 위해 알려진 제품이나 승인된 부형제의 수가 제한적이기 때문에 바이오 제약사들은 더욱 큰 어려움을 겪고 있습니다. 따라서 이러한 문제를 해결하기 위해 연구자들은 새롭고 혁신적인 접근법을 개발하고 있습니다. 예를 들어, 지질 기반 부형제(HMC 부형제)의 안정성을 유지하기 위해 연구자들은 지방산 폴리글리세린 에스테르(PGFA)를 적용하고 있습니다. 현재 이 제품들은 COVID-19 백신 개발에서 수요가 증가하고 있습니다.

바이오의약품 부형제 시장 보고서 하이라이트:

• 탄수화물 기반 제품 부문은 2022년 바이오의약품 부형제 시장에서 35.80%의 매출 점유율을 차지했으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다. 전분, 자당, 덱스트로스가 다양한 의약품 제제에 광범위하게 사용되는 것이 이 부문의 지배적인 점유율의 주요 요인으로 추정됩니다.
• 폴리올 분야는 예측 기간 동안 가장 빠른 CAGR 5.77%를 기록할 것으로 예상됩니다. 폴리올은 특정 과일, 채소 및 무설탕 감미료에서 발견되는 당 알코올입니다. 이 분야의 성장은 단백질 치료제에 대한 수요 증가에 기인합니다. 폴리올은 강장제와 안정성을 높이기 위해 단백질 제제에 첨가됩니다.
• 지역별로는 북미가 2022년 바이오의약품 부형제 시장에서 가장 높은 점유율을 차지했습니다. 이 지역의 성장은 주요 기업의 존재, 의약품 개발 증가, 인구 증가 등 여러 가지 요인에 기인하는 것으로 보입니다. 이 지역의 기업들은 바이오의약품 부형제를 개발하기 위해 자주 공동 연구를 수행합니다.
• 아시아태평양은 의약품 개발에 참여하는 대형 CMO의 존재로 인해 예측 기간 동안 6.0% 이상의 급격한 성장이 예상됩니다. 중국, 인도, 한국과 같은 국가들이 바이오시밀러 개발에 크게 관여하고 있습니다. 이 지역에서 바이오시밀러가 광범위하게 개발되고 있는 이유는 여러 가지가 있는데, 예를 들어 저렴한 가격, 좋은 규제 프레임워크, 비용 측면의 이점, 큰 인구 기반 등이 있습니다.

목차

제1장 바이오의약품 부형제 시장 : 조사 방법과 범위

제2장 바이오의약품 부형제 시장 : 주요 요약

• 시장 전망
• 제품 현황
• 경쟁 상황 현황

제3장 바이오의약품 부형제 시장 : 시장 변수, 동향 및 범위

• 시장 계통 전망
• 시장 역학
• 업계 분석 툴

제4장 바이오의약품 부형제 시장 : 제품 비지니스 분석

• 바이오의약품 부형제 시장 : 제품 변동 분석
• 가용화제 및 계면활성제/유화제
• 폴리올
• 탄수화물
• 특수 부형제

제5장 바이오의약품 부형제 시장 : 지역 비지니스 분석

• 지역 시장 현황
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제6장 바이오의약품 부형제 시장 : 경쟁 상황

• 기업 분류
• 전략 매핑
• 기업의 시장 점유율 분석, 2022년
• 기업 개요

제7장 KOL의 추천사항/애널리스트의 견해

ksm

영문 목차

영문목차

Biopharmaceutical Excipients Market Growth & Trends:

The global biopharmaceutical excipients market size is expected to reach USD 3.76 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 5.50% from 2023 to 2030. The increasing focus of pharmaceutical players on the generic market, rising adoption of multifunctional excipients, and patent expiry of biological actives are the key factors propelling market growth. Furthermore, the cost-efficiency & competency of manufacturers and the chemical and physical instability of biopharmaceuticals are boosting the development of excipients, thus propelling the market.

The demand for biosimilars has increased in recent years, which has in turn led to a rise in the demand for biopharmaceutical excipients. Supporting factors such as patent expirations, increasing government funding, patient demographics, and rising affordability have propelled the adoption of biosimilars across the globe. In addition, the rapidly evolving healthcare infrastructure in developing economies has increased their use in the production of biogenerics. Furthermore, the introduction of well-framed legislation to ensure proper regulatory and testing standards for biosimilars globally is set to ease market entry for manufacturers.

Moreover, the growing acceptance of multi-functional biopharmaceutical excipients in industries is also driving market growth. They are efficient and effective in enhancing the manufacturing process for biopharmaceuticals. Associated advantages include better product quality, improved productivity, and reduced operating costs. The success of COVID-19 vaccines majorly relies on their efficiency, which has been enhanced by using efficient drug delivery systems; this offers immense lucrative opportunities for market entities.

Key operating players in the market are focusing on the development and launch of novel biopharmaceutical excipients. For instance, in April 2021, DFE Pharma introduced a new excipient product line 'BioHale' to address global supply challenges for biopharmaceutical companies. Furthermore, the geographical expansion of manufacturing facilities is increasing, owing to the rising demand for biopharmaceutical excipients. For instance, in May 2022, DFE Pharma opened a new facility in India to offer fast-track formulation services, including excipients, for pharmaceutical players to achieve the right formulations.

However, issues pertaining to the supply chain in the biopharmaceutical industry and challenges in the development of excipients for biologics are expected to hamper the market during the forecast period. Selecting the right excipient for biopharmaceuticals is a challenging and complicated task, as an excipient effective in one formulation may cause degradation or aggregation of the protein in another. A limited number of known & approved products for the stabilization of protein further increases challenges for biopharma manufacturers. Hence, to deal with these challenges, researchers are developing new and innovative approaches. For instance, to maintain the stability of lipid-based excipients (HMC excipients), researchers have applied polyglycerol esters of fatty acids (PGFAs). Currently, these products are witnessing an increasing demand for the development of COVID-19 vaccines.

Biopharmaceutical Excipients Market Report Highlights:

• Thecarbohydrate-based products segment dominated the market for biopharmaceutical excipients in 2022 with a revenue share of 35.80%, and this trend is expected to continue through the forecast period. The extensive use of starch, sucrose, and dextrose in various drug formulations can be primarily attributed to the dominant share of the segment
• The polyols segment is expected to witness the fastest CAGR of 5.77% during the projection period. Polyols are sugar alcohols found in certain fruits, vegetables, and sugar-free sweeteners. The segment growth can be attributed to the increasing demand for protein therapeutics. Polyols are added in protein formulations for increasing tonicity and stability
• In terms of region, North America held the highest share in the market for biopharmaceutical excipients in 2022.The regional growth can be attributed to several factors such as the presence of key players, increasing drug development, and a large population base. Companies in this region are collaborating frequently to develop biopharmaceutical excipients
• In Asia Pacific, the market is expected to witness the fastest growth rate of over 6.0% during the forecast period, owing to the presence of large CMOs involved in drug development in the region. Countries such as China, India, and South Korea are majorly involved in the development of biosimilars. There are several reasons for the extensive development of biosimilars in this region, such as affordability, favorable regulatory framework, cost advantages, and the presence of a large population base

Table of Contents

Chapter 1 Biopharmaceutical Excipients Market: Research Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Product Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2 Biopharmaceutical Excipients Market: Executive Summary

• 2.1 Market Outlook
• 2.2 Product Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Biopharmaceutical Excipients Market: Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Related/Ancillary Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Drivers Analysis
    • 3.2.1.1 Chemical And Physical Instability Of Biopharmaceuticals Is Boosting The Development Of Excipients
    • 3.2.1.2 Increase In Focus Of Pharmaceutical Players On Biogeneric Market
    • 3.2.1.3 Cost Effective And Competency Of Manufacturers
    • 3.2.1.4 Patent Expiry Of Biological Actives
    • 3.2.1.5 Rising Adoption Of Multifunctional Excipients
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Challenges In Development Of Excipients For Biologics
    • 3.2.2.2 Issues Pertaining To Supply Chain In Biopharmaceutical Industry
• 3.3 Industry Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Pestel Analysis

Chapter 4 Biopharmaceutical Excipients Market: Product Business Analysis

• 4.1 Biopharmaceutical Excipients Market: Product Movement Analysis
• 4.2 Solubilizes & Surfactants/Emulsifiers
  • 4.2.1 Solubilizes & Surfactants/Emulsifiers Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.2.2 Triglycerides
    • 4.2.2.1 Triglycerides Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.2.3 Esters
    • 4.2.3.1 Esters Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.2.4 Others
    • 4.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
• 4.3 Polyols
  • 4.3.1 Polyols Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.3.2 Mannitol
    • 4.3.2.1 Mannitol Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.3.3 Sorbitol
    • 4.3.3.1 Sorbitol Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.3.4 Others
    • 4.3.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
• 4.4 Carbohydrates
  • 4.4.1 Carbohydrates Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.4.2 Dextrose
    • 4.4.2.1 Dextrose Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.4.3 Sucrose
    • 4.4.3.1 Sucrose Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.4.4 Starch
    • 4.4.4.1 Starch Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 4.4.5 Others
    • 4.4.5.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
• 4.5 Specialty Excipients
  • 4.5.1 Specialty Excipients Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)

Chapter 5 Biopharmaceutical Excipients Market: Regional Business Analysis

• 5.1 Regional Market Snapshot
• 5.2 North America
  • 5.2.1 North America Biopharmaceutical Excipients Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume In Tons)
  • 5.2.2 U.S.
    • 5.2.2.1 U.S. Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.2.2.2 Key Country Dynamics
    • 5.2.2.3 Regulatory Framework
    • 5.2.2.4 Reimbursement Scenario
  • 5.2.3 Canada
    • 5.2.3.1 Canada Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.2.3.2 Key Country Dynamics
    • 5.2.3.3 Regulatory Framework
    • 5.2.3.4 Reimbursement Scenario
• 5.3 Europe
  • 5.3.1 Europe Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
  • 5.3.2 UK
    • 5.3.2.1 UK Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.2.2 Key Country Dynamics
    • 5.3.2.3 Regulatory Framework
    • 5.3.2.4 Reimbursement Scenario
  • 5.3.3 Germany
    • 5.3.3.1 Germany Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.3.2 Key Country Dynamics
    • 5.3.3.3 Regulatory Framework
    • 5.3.3.4 Reimbursement Scenario
  • 5.3.4 Spain
    • 5.3.4.1 Spain Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.4.2 Key Country Dynamics
    • 5.3.4.3 Regulatory Framework
    • 5.3.4.4 Reimbursement Scenario
  • 5.3.5 France
    • 5.3.5.1 France Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.5.2 Key Country Dynamics
    • 5.3.5.3 Regulatory Framework
    • 5.3.5.4 Reimbursement Scenario
  • 5.3.6 Italy
    • 5.3.6.1 Italy Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.6.2 Key Country Dynamics
    • 5.3.6.3 Regulatory Framework
    • 5.3.6.4 Reimbursement Scenario
  • 5.3.7 Denmark
    • 5.3.7.1 Denmark Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.7.2 Key Country Dynamics
    • 5.3.7.3 Regulatory Framework
    • 5.3.7.4 Reimbursement Scenario
  • 5.3.8 Sweden
    • 5.3.8.1 Sweden Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.8.2 Key Country Dynamics
    • 5.3.8.3 Regulatory Framework
    • 5.3.8.4 Reimbursement Scenario
  • 5.3.9 Norway
    • 5.3.9.1 Norway Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.3.9.2 Key Country Dynamics
    • 5.3.9.3 Regulatory Framework
    • 5.3.9.4 Reimbursement Scenario
• 5.4 Asia Pacific
  • 5.4.1 Asia-Pacific Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
  • 5.4.2 Japan
    • 5.4.2.1 Japan Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.2.2 Key Country Dynamics
    • 5.4.2.3 Regulatory Framework
    • 5.4.2.4 Reimbursement Scenario
  • 5.4.3 CHINA
    • 5.4.3.1 China Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.3.2 Key Country Dynamics
    • 5.4.3.3 Regulatory Framework
    • 5.4.3.4 Reimbursement Scenario
  • 5.4.4 India
    • 5.4.4.1 India Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.4.2 Key Country Dynamics
    • 5.4.4.3 Regulatory Framework
    • 5.4.4.4 Reimbursement Scenario
  • 5.4.5 South Korea
    • 5.4.5.1 South Korea Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.5.2 Key Country Dynamics
    • 5.4.5.3 Regulatory Framework
    • 5.4.5.4 Reimbursement Scenario
  • 5.4.6 Thailand
    • 5.4.6.1 Thailand Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.6.2 Key Country Dynamics
    • 5.4.6.3 Regulatory Framework
    • 5.4.6.4 Reimbursement Scenario
  • 5.4.7 Australia
    • 5.4.7.1 Australia Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.4.7.2 Key Country Dynamics
    • 5.4.7.3 Regulatory Framework
    • 5.4.7.4 Reimbursement Scenario
• 5.5 Latin America
  • 5.5.1 Latin America Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
  • 5.5.2 Brazil
    • 5.5.2.1 Brazil Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.5.2.2 Key Country Dynamics
    • 5.5.2.3 Regulatory Framework
    • 5.5.2.4 Reimbursement Scenario
  • 5.5.3 Mexico
    • 5.5.3.1 Mexico Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.5.3.2 Key Country Dynamics
    • 5.5.3.3 Regulatory Framework
    • 5.5.2.4 Reimbursement Scenario
  • 5.5.4 Argentina
    • 5.5.4.1 Argentina Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.5.4.2 Key Country Dynamics
    • 5.5.4.3 Regulatory Framework
    • 5.5.4.4 Reimbursement Scenario
• 5.6 MEA
  • 5.6.1 MEA Biopharmaceutical Excipients Market 2018 - 2030 (USD Million) (Volume In Tons)
  • 5.6.2 South Africa
    • 5.6.2.1 South Africa Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.6.2.2 Key Country Dynamics
    • 5.6.2.3 Regulatory Framework
    • 5.6.2.4 Reimbursement Scenario
  • 5.6.3 Saudi Arabia
    • 5.6.3.1 Saudi Arabia Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.6.3.2 Key Country Dynamics
    • 5.6.3.3 Regulatory Framework
    • 5.6.3.4 Reimbursement Scenario
  • 5.6.4 UAE
    • 5.6.4.1 UAE Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.6.4.2 Key Country Dynamics
    • 5.6.4.3 Regulatory Framework
    • 5.6.2.4 Reimbursement Scenario
  • 5.6.5 Kuwait
    • 5.6.5.1 Kuwait Biopharmaceutical Excipients Market, 2018 - 2030 (USD Million) (Volume In Tons)
    • 5.6.5.2 Key Country Dynamics
    • 5.6.5.3 Regulatory Framework
    • 5.6.5.4 Reimbursement Scenario

Chapter 6 Biopharmaceutical Excipients Market: Competitive Landscape

• 6.1 Company Categorization
• 6.2 Strategy Mapping
  • 6.2.1 New product launch
  • 6.2.2 Partnerships
  • 6.2.3 Acquisition
  • 6.2.4 Collaboration
  • 6.2.5 Funding
• 6.3 Company Market Share Analysis, 2022
• 6.4 Company Profiles
  • 6.4.1 MERCK KGAA
    • 6.4.1.1 Company overview
    • 6.4.1.2 Financial performance
    • 6.4.1.3 Product benchmarking
    • 6.4.1.4 Strategic initiatives
  • 6.4.2 SIGNET EXCIPIENTS PVT. LTD.
    • 6.4.2.1 Company overview
    • 6.4.2.2 Financial performance
    • 6.4.2.3 Product benchmarking
    • 6.4.2.4 Strategic initiatives
  • 6.4.3 Sigachi Industries Pvt. Ltd
    • 6.4.3.1 Company overview
    • 6.4.3.2 Financial performance
    • 6.4.3.3 Product benchmarking
    • 6.4.3.4 Strategic initiatives
  • 6.4.4 ASSOCIATED BRITISH FOODS
    • 6.4.4.1 Company overview
    • 6.4.4.2 Financial performance
    • 6.4.4.3 Product benchmarking
    • 6.4.4.4 Strategic initiatives
  • 6.4.5 SPECTRUM CHEMICAL MANUFACTURING CORP.
    • 6.4.5.1 Company overview
    • 6.4.5.2 Financial performance
    • 6.4.5.3 Product benchmarking
    • 6.4.5.4 Strategic initiatives
  • 6.4.6 ROQUETTE FRERES
    • 6.4.6.1 Company overview
    • 6.4.6.2 Financial performance
    • 6.4.6.3 Product benchmarking
    • 6.4.6.4 Strategic initiatives
  • 6.4.7 DFE PHARMA
    • 6.4.7.1 Company overview
    • 6.4.7.2 Financial performance
    • 6.4.7.3 Product benchmarking
    • 6.4.7.4 Strategic initiatives
  • 6.4.8 CLARIANT
    • 6.4.8.1 Company overview
    • 6.4.8.2 Financial performance
    • 6.4.8.3 Product benchmarking
    • 6.4.8.4 Strategic initiatives
  • 6.4.9 COLORCON
    • 6.4.9.1 Company overview
    • 6.4.9.2 Financial performance
    • 6.4.9.4 Product benchmarking
    • 6.4.9.5 Strategic initiatives
  • 6.4.10 RETTENMAIER & SOHNE GMBH + CO KG
    • 6.4.10.1 Company overview
    • 6.4.10.2 Financial performance
    • 6.4.10.3 Product benchmarking
    • 6.4.10.4 Strategic initiatives
  • 6.4.11 BASF SE
    • 6.4.11.1 Company overview
    • 6.4.11.2 Financial performance
    • 6.4.11.3 Product benchmarking
    • 6.4.11.4 Strategic initiatives
  • 6.4.12 EVONIK INDUSTRIES AG
    • 6.4.12.1 Company overview
    • 6.4.12.2 Financial performance
    • 6.4.12.3 Product benchmarking
    • 6.4.12.4 Strategic initiatives
  • 6.4.13 IMCD
    • 6.4.12.1 Company overview
    • 6.4.12.2 Financial performance
    • 6.4.12.3 Product benchmarking
    • 6.4.12.4 Strategic initiatives

Chapter 7 KOL Recommendations/Analyst Perspective

관련자료